Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Joins Ensemble To Develop An Oral IL-17 Blocker

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis is the latest big pharma to partner with Ensemble to develop oral small molecules against traditional biologic targets. Novartis will develop Ensemble’s synthetic macrocycle drug targeting IL-17, a pathway the big pharma knows well.

Advertisement

Related Content

Biocon’s Alzumab Is Priced At Half Of Its Rival Brands, But Will It Change The Game?
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
Ensemble Therapeutics Corp.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel